Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT05199272

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

A Phase 1/2a, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients With Advanced Solid Malignancies

Sponsor: 23andMe, Inc.

Conditions Cancer With A High Tumor Mutational Burden Clear Cell Renal Cell Carcinoma Epithelial Ovarian Cancer Extensive-stage Small-cell Lung Cancer Fallopian Tube Cancer MSI-H Cancer Neuroendocrine Tumors Primary Peritoneal Carcinoma Solid Tumor

Interventions 23ME-00610

Updated 18 times since 2022 Last updated: Nov 13, 2024 Started: Dec 29, 2021 Primary completion: Mar 31, 2025 Completion: Mar 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05199272, this PHASE1/PHASE2 trial focuses on Cancer With A High Tumor Mutational Burden and Clear Cell Renal Cell Carcinoma and remains ongoing. Sponsored by 23andMe, Inc., it has been updated 18 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

18 versions recorded

Dec 2024 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2
Sep 2024 — Dec 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2
May 2024 — Jun 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 13 earlier versions

Jan 2024 — May 2024 [monthly]

Recruiting PHASE1_PHASE2
Aug 2023 — Jan 2024 [monthly]

Recruiting PHASE1_PHASE2
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE1_PHASE2
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE1_PHASE2
May 2023 — Jun 2023 [monthly]

Recruiting PHASE1_PHASE2
Apr 2023 — May 2023 [monthly]

Recruiting PHASE1_PHASE2
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE1_PHASE2
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE1_PHASE2

Phase: PHASE1 → PHASE1_PHASE2
Dec 2022 — Feb 2023 [monthly]

Recruiting PHASE1
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE1
Jul 2022 — Nov 2022 [monthly]

Recruiting PHASE1
May 2022 — Jul 2022 [monthly]

Recruiting PHASE1
Feb 2022 — May 2022 [monthly]

Recruiting PHASE1

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

23andMe, Inc.

Data source: 23andMe, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Detroit, United States , Fairfax, United States , Houston, United States , Lake Success, United States , Nashville, United States , New Hyde Park, United States , Ottawa, Canada , Palo Alto, United States , Portland, United States and 2 more locations